Literature DB >> 2912934

Response of human tumor cell lines in vitro to fractionated irradiation.

J H Matthews1, B E Meeker, J D Chapman.   

Abstract

The surviving fraction of human tumor cell lines after 2 Gy (SF2) varies between 0.1 and 0.8. It has been postulated that differences in inherent radiosensitivity of tumor cells are a major determinant of radiation response in vivo. Assays of inherent radiosensitivity based on acute survival are being developed as predictors of tumor response which often assume that the same inherent radiosensitivity persists throughout a fractionated treatment. We have investigated the response of 2 human tumor cell lines (A549 and MCF7) with different inherent radiosensitivities to in vitro fractionated irradiation. A549 cells had an SF2 of 0.62 and a mean inactivation dose (D) of 3.07 Gy whereas MCF7 cells had an SF2 of 0.30 and a D of 1.52 Gy. Split dose repair capacity (at equal survival levels) was less for A549 than for MCF7 cells and recovery kinetics for both cell lines were substantially longer than those of rodent cell lines. Survival after 5 fractions of 2 Gy given 12 hr apart at 37 degrees C was near to that predicted from the acute survival curve, assuming complete repair and no proliferation. Acute survival of A549 cells which survived 5 fractions of 2 Gy given 12 hr apart was similar to the acute survival of unirradiated cells. When A549 cells were incubated at 22 degrees C between 5 fractions of 2 Gy given 12 hr apart, proliferation and split dose repair were substantially inhibited. These studies support the proposals to use in vitro inherent radiosensitivity assays for the prediction of in vivo response of tumors to fractionated treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2912934     DOI: 10.1016/0360-3016(89)90020-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Assessment of contralateral mammary gland dose in the treatment of breast cancer using accelerated hypofractionated radiotherapy.

Authors:  Maria Tolia; Kalliopi Platoni; Andreas Foteineas; Maria-Aggeliki Kalogeridi; Anna Zygogianni; Nikolaos Tsoukalas; Mariangela Caimi; Niki Margari; Maria Dilvoi; Panagiotis Pantelakos; John Kouvaris; Vassilis Kouloulias
Journal:  World J Radiol       Date:  2011-09-28

2.  In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.

Authors:  Marion T Weigel; Linda Dahmke; Christian Schem; Dirk O Bauerschlag; Katrin Weber; Peter Niehoff; Maret Bauer; Alexander Strauss; Walter Jonat; Nicolai Maass; Christoph Mundhenke
Journal:  BMC Cancer       Date:  2010-08-09       Impact factor: 4.430

3.  Effects of radiation fractionation on four squamous cell carcinoma lines with dissimilar inherent radiation sensitivity.

Authors:  K Pekkola-Heino; J Kulmala; P Klemi; T Lakkala; K Aitasalo; H Joensuu; R Grenman
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy.

Authors:  Shahzad Raza; Stella C Lymberis; Raquel Ciervide; Deborah Axelrod; Maria Fenton-Kerimian; Chiara Magnolfi; Barry Rosenstein; J Keith Dewyngaert; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-05-08       Impact factor: 6.244

5.  Radiation Sensitivity of Adipose-Derived Stem Cells Isolated from Breast Tissue.

Authors:  Annemarie Baaße; Friederike Machoy; Dajana Juerß; Jana Baake; Felix Stang; Toralf Reimer; Björn Dirk Krapohl; Guido Hildebrandt
Journal:  Int J Mol Sci       Date:  2018-07-07       Impact factor: 5.923

6.  Kinetic modeling of tumor regression incorporating the concept of cancer stem-like cells for patients with locally advanced lung cancer.

Authors:  Hualiang Zhong; Stephen Brown; Suneetha Devpura; X Allen Li; Indrin J Chetty
Journal:  Theor Biol Med Model       Date:  2018-12-27       Impact factor: 2.432

Review 7.  Hypofractionated Postmastectomy Radiation Therapy.

Authors:  Mutlay Sayan; Zeinab Abou Yehia; Nisha Ohri; Bruce G Haffty
Journal:  Adv Radiat Oncol       Date:  2020-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.